Liver cancer exhibits the fourth most common cause of cancer-associated mortality worldwide. Due to the rapid growth, solid tumors undergo severe hypoxia and produce high levels of extracellular adenosine to maintain homeostasis. A previous study indicated that the hypoxic condition in liver cancer increased hepatic adenosine, which is known to facilitate cancer survival and proliferation. Extracellular adenosine has been revealed to regulate pathological and physiological processes in cells and tissues. However, its pathophysiological role in liver cancer remains undetermined. Emerging evidence has indicated that the adenosine A2B receptor promotes the progression of liver cancer. Therefore, it was hypothesized that HIF-1α is a transcriptional regulator of A2B in human liver cancer. The current study determined A2B expression of a number of liver cancer cell lines and performed functional studies of HIF-1α as a master transcriptional regulator of hepatic A2B signaling during hypoxic conditions. The current study aimed to identify the promoter region of A2B, which has a hypoxia response element, by performing luciferase assays. The present study demonstrated that reduced HIF-1α expression is associated with low expression of A2B, and HIF-1α overexpression is associated with A2B induction. Furthermore, the siRNA-mediated downregulation of A2B inhibited the growth and proliferation of HepG2, which is a liver cancer cell line. The relationship between HIF-1α and A2B expression was also identified in human liver cancer specimens. In conclusion, the current study indicated that A2B is induced by the HIF-1α transcriptional regulator during hypoxia, and it may be a potential pharmacologic and therapeutic target for the treatment of patients with liver cancer.
Introduction
Liver cancer is the fourth leading cause of cancer mortality worldwide (1, 2) . Despite significant progress over the past decades, the clinical outcomes of patients with liver cancer remain poor and an in-depth understanding of the molecular pathogenesis of liver cancer could facilitate the development of novel diagnostic and therapeutic techniques.
Adenosine is an endogenous nucleoside that controls many physiological processes through interactions with adenosine receptors, such as A1, A2A, A2B, and A3 (3) . Adenosine A2 receptors have two segmented isoforms; high-affinity A2A receptor which is highly concentrated in the striatum, and relatively low-affinity A2B receptors which present throughout the brain (4) . Generally, adenosines can be found eluted into the extracellular matrix of ordinary solid organs under low-oxygen conditions (5) . However, in cancerous organs, the signaling pathway generated between adenosine and its receptor has been shown to coordinate adenosine accumulation and the increased levels of adenosine in the extracellular fluid of solid tumors stimulate cancer cell proliferation and tumor angiogenesis (6) . The relationship between the tumor progression and adenosine A2B receptor expression has been investigated in many types of tumors including bladder (7) , breast (8) , colon (9) , and prostate (10) cancers. While some researchers have shown that A2B is highly expressed in cancerous tissues in patients with HCC (11) , the regulatory pathways and the function of A2B in liver cancer remain undiscovered.
The adenosine A2B receptor is reported to be transcriptionally induced by tumor necrosis factor-alpha (TNF-α) (12) , interferon-gamma (IFN-γ) (13) , and hypoxia-inducible factor-1α (HIF-1α) (14, 15) . HIF-1α is an oxygen-regulated subunit of HIF-1, a heterodimeric transcription factor consisting of α-and β-subunits. Intra-tumoral hypoxia is the major cause of increased HIF-1 activity in human HCC (16) , and HIF-1α protein stabilization in cancer cells leading to the upregulation of multiple HIF-1 target genes that are required for HCC tumor growth, as demonstrated by both genetic and pharmacologic loss-of-function studies (17) . HIF-1α mediated expression of adenosine A2B receptor activations in hypoxia has reported in endothelial cells (15) , acute lung injury (18) , and breast cancer (19) . In addition to this, many researchers suggested that hypoxia is one factor for inducing A2B expressions, however, direct HIF-1α mediated A2B increment during tumor progression, especially in liver cancer has not been investigated yet. Therefore, we designed experiments to verify whether transcriptional regulation pathways control the endogenous hepatic adenosine signaling during a low-oxygen condition of liver cancer cells. Furthermore, we also investigated the potential HIF-1α binding regions in the A2B promoter genes. We believe our study will contribute to the development of new therapeutic targets to treat liver cancers.
Materials and methods
Cell culture and hypoxic conditions. We purchased human liver cancer cell lines, including HepG2 (KCLB no. 88065; passage 21), the hepatoblastoma cell line (20) , and the hepatocellular carcinoma (HCC) cell lines SK-Hep1 (KCLB no. 30052; passage 49) and SNU-449 (KCLB no. 00449; passage 28) from the Korean Cell Line Bank (KCLB; Seoul, Republic of Korea). HepG2 and SK-Hep1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) high-glucose (Hyclone; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (FBS; Mediatech) and 100 U/ml penicillin/streptomycin (HyClone). The HCC SNU-449 cells were maintained in RPMI-1640 (Invitrogen; Thermo Fisher Scientific, Inc.), supplemented with 10% FBS and 100 U/ml penicillin/streptomycin. We cultured all the cells in a standard humidified incubator at 37̊C in an atmosphere of 5% CO 2 . To induce hypoxic conditions, we placed cells in a hypoxia incubator (MCO-18M; Sanyo) filled with a mixture of 5% CO 2 , 94.5% N 2 , and 0.5% O 2 gas. Authentication of the cell lines was done using short tandem repeat (STR) profiling by the Korean Cell Line Bank (Seoul National University College of Medicine, Seoul, Republic of Korea; http://cellbank.snu. ac.kr/) with proper STR references. The cell lines were tested for mycoplasma contamination before use and were negative for mycoplasma.
Establishment of A2B luciferase constructs. We used a pGL3 basic luciferase vector as a control plasmid and performed luciferase assays with previously designed constructs (15) . The full-length construct (1095 bp) had a hypoxia-response element (HRE). The other truncated construct (477 bp) lacked an HRE. Additionally, we used a mutant form of the 1095 bp plasmid with a modified sequence (ACGTG was altered to AATCG).
A2B reporter assay. To confirm the transcriptional activity of the adenosine A2B receptor, we used HepG2 cells as an easily transfectable cellular model. First, to investigate the A2B promoter region, we used HepG2 cells to measure the reporter gene activity. We co-transfected cells with 2 µg of A2B-Luc promoter-reporter and 0.02 µg Renilla reporter vector for 24 h using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Next, we exposed the cells to hypoxic conditions for up to 12 h. To prepare whole protein lysates, we used 1x passive lysis buffer (cat no. E1910; Promega). To perform the luciferase assay, we followed the protocol of the Dual-Luciferase Reporter Assay (Promega).
RNA interference. Small interfering RNAs (siRNA) specific to either HIF-1α (HIF-1α-siRNA), A2B (A2B-siRNA), or scrambled sequences (scr-siRNA) were prepared by Bioneer Corporation. We used 0.5 µg of siRNA for transfections using Lipofectamine ® 2000 reagent (Invitrogen). The sequences of siRNAs were: Scrambled-siRNA (scr-siRNA), sense, 5'-CCU ACG CCA CCA AUU UCG U (dTdT)-3' , antisense, 5'-ACG AAA UUG GUG GCG UAG G (dTdT)-3'; HIF-1α-siRNA, sense, 5'-GUG GUU GGA UCU AAC ACU A (dTdT)-3', antisense, 5'-UAG UGU UAG AUC CAA CCA C (dTdT)-3'; A2B-siRNA, sense, 5'-GAG ACU UCC GCU ACA CUU U (dTdT)-3', antisense, 5'-AAA GUG UAG CGG AAG UCU C (dTdT)-3'.
HIF-1α plasmid overexpression. We seeded HepG2 cells into 6-well plates at a density of 1.0x10 6 cells per well and incubated them for 24 h at 37̊C. The cells were transfected with a HIF-1-pcDNA3.1-expressing plasmid using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). We confirmed HIF-1α overexpression by western blot. The negative control plasmid pcDNA3.1(+) and the HIF-1-pcDNA3.1-expressing plasmids were purchased from Addgene. We treated cells with range from 3 to 300 nM of echinomycin (cat no. 5520; Tocris Bioscience), a specific inhibitor of HIF-1 DNA binding activity, to achieve chemical interference of HIF activity.
BrdU assay. Exponentially growing HepG2 cells were digested, centrifuged, collected, and inoculated into 96-well culture plates at a density of 5.0x10 3 cells/well. After culturing for 24 h in DMEM containing 10% FBS, the cells were transfected with scrambled-siRNA (scr-siRNA) and A2B-siRNA. HepG2 cell proliferation activity was analyzed using BrdU cell proliferation assay kits (cat no. 2750; Millipore), 24, 48, 72, and 96 h after siRNA transfection. The BrdU reagent was added to the culture wells at each time point, and the plates were incubated at 37̊C for an additional 4 h. The cells were then fixed, and the BrdU levels were detected colorimetrically following the manufacturer's instructions. To plot the growth curve, a microplate reader (Sunrise TECAN, Labx, Canada) was used to measure absorbance at 450 nm. Experiments were repeated four times.
Cell growth and viability test. Cell growth and viability were determined by performing a 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 12 well cell culture plates (NEST Biotechnology). HepG2 cells were seeded at a density of 5.0x10 4 per well for 24 h and cultured in DMEM containing 10% FBS. The cells were then transfected with scr-siRNA or A2B-siRNA. After incubation for 24, 48, and 72 h, 20 µl of MTT solution (5 mg/ml in phosphate buffer saline) was added to each well, and the plates were incubated in the dark for 4 h at 37̊C. Cell growth and viability were expressed as the percentage of absorbance of MTT-treated cells relative to that of untreated cells at a wavelength of 540 nm. Measurements for all treatment groups were taken four times.
Patient tissue samples. We collected five individual human HCC specimens from patients with HCC, who visited the Asan Medical Center (Division of Liver Transplantation and Hepatobiliary Surgery; Seoul, Republic of Korea) between 2014 and 2015 (Table I) . None of the patients received any form of treatment before surgical procedures. We separately collected small pieces of the tumor and adjacent normal tissues and snap-froze them into liquid nitrogen. Frozen samples were stored at -80̊C until use. The Institutional Review Board of Asan Medical Center reviewed and approved the collection and use of patient specimens (approval no. 2016-0582). All patients who provided tissue samples agreed to donate their specimens and provided written informed consents.
RNA extraction and RT-PCR. We isolated total RNA from human livers and liver cancer cells using QIAzol reagent (Qiagen). We homogenized the frozen tissues and liver cancer cell suspensions in QIAzol reagent. The homogenates were mixed thoroughly after adding chloroform and were centrifuged at 16,000 x g for 15 min. The aqueous phase was removed, and the RNA was precipitated with isopropyl alcohol. RNA was pelleted, washed with 70% ethanol, dried, and eluted using DEPC-treated water. We used a spectrophotometer Nanodrop 2000 (Nanodrop) to quantify the final concentration.
We quantified transcription of relevant genes using real-time reverse transcription-polymerase chain reaction (RT-PCR) in a CFX Connect Real-Time PCR Detection System (Bio-Rad) with 5x HOT FIREPol EvaGreen qPCR Supermix (Solis BioDyne), according to the manufacturer's instructions. In brief, the samples were first denatured at 95̊C for 15 min, followed by 40 cycles of denaturation at 95̊C for 15 sec, annealing at 55̊C-60̊C for 15 sec, and elongation at 72̊C for 20 sec. The data are expressed as the fold changes in the treatment groups relative to the control level and were normalized to GAPDH levels using the delta-delta Ct methods (21) . Table II lists the sense and antisense primer sequences.
Protein isolation and western blotting. We extracted protein samples from ~2.0x10 6 cells or 70 mg of frozen liver tissues. The samples were homogenized in lysis buffer (RIPA; Biosesang), quantified with BCA protein assay kit (Thermo Fisher Scientific, Inc.), and immunoblotted with anti-adenosine A2B receptor antibody (1:1,000 dilution; ab40002, Abcam) followed by rabbit anti-goat IgG HRP (1:20,000 dilution; A5420, Sigma-Aldrich); or anti-HIF-1α antibody (1:1,000 dilution; cat no. 610959, BD Biosciences) followed by goat anti-mouse IgG HRP (1;5,000; sc-2005, Santa Cruz Biotechnology). We also probed the nitrocellulose membranes with actin-peroxidase conjugate (1:20,000 dilution; A3854, Sigma-Aldrich). The protein signals were detected using an enhanced chemiluminescence solution (SuperSignal™ West Femto; Thermo Fisher Scientific, Inc.), and images were obtained using the ImageQuant LAS 4000 system (GE Healthcare Biosciences).
Statistical analysis.
We performed all statistical analyses using the GraphPad Prism 6.0 software (GraphPad Software).
All other data are presented as the mean ± SD. For western blot analyses, we repeated each experiment three times. We used a one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison test. P<0.05 was considered to indicate a statistically significant difference.
Results
Hypoxia triggered A2B induction is time-dependent in liver cancer cells. In this study, we investigated whether A2B is upregulated under hypoxic conditions or not. Thus, we grew three liver cancer cell lines, SK-Hep1, HepG2, and SNU449, under hypoxic conditions. We consistently detected the significant expression of only A2B mRNA levels compared to the expression of other receptor genes (A1, A2A, and A3) under low-oxygen conditions (Fig. 1A) . As shown, the A2B mRNA level and protein expressions were expressed in a time-dependent manner during hypoxia in SK-Hep1 cells (Fig. 1B) . Additionally, A2B is upregulated under hypoxic conditions in HepG2 (Fig. 1C ) and SNU449 cells (Fig. 1D) . These data reveal a selective induction of A2B during hypoxic conditions.
HIF-1α directly regulated the expression of A2B by binding to the HRE in the A2B promoter region. To verify if A2B is transcriptionally induced by HIF-1α, we first searched for the human A2B promoter region, which has an HRE, containing -642 to -647 bp, at the 5'-CACGTGG-3' sequence and its typical HIF-1α ancillary HAS site (5'-CGGGGAG-3') at -546 to -541 ( Fig. 2A) . To investigate the function of the HIF-1α binding site, we used two modified constructs, a full-length promoter construct (1095 bp) and a truncated construct (477 bp) of HIF-1α ( Fig. 2B ). As shown in the results, the full-length HRE construct-transfected cells had significantly higher activity than the truncated construct. Next, to define whether the full-length construct was acted upon by HIF-1α, we performed luciferase assays with site-directed mutagenesis constructs. The mutant form of this construct had an HRE AATCG change from ACGTG (Fig. 2C ). The mutant construct (1095 Mut) exhibited low luciferase assay activity levels, as hypothesized. These results confirmed the A2B promoter region has an HRE site in it.
HIF-1α upregulates A2B expression during hypoxia.
To confirm the HRE function within the promoter region of A2B, we performed experiments with HIF-1α siRNA and HIF-1α pcDNA plasmids. We transfected HIF-1α siRNA for 12 h (Fig. 3A ) and then exposed the cells to hypoxia for different durations of time ( Fig. 3B ). HIF-1α siRNA-transfected cells displayed low A2B expression levels while HIF-1α is being absent. In contrast, the cells overexpressing HIF-1α exhibited high A2B expression levels ( Fig. 3C ) and hypoxia time dependency (Fig. 3D ). Moreover, we treated cells with echinomycin (a cell-permeable inhibitor of HIF-1α-mediated gene transcription) and observed a dose-dependent decrease in the A2B mRNA and protein expression levels during low-oxygen conditions ( Fig. 3E and F) . Our results suggest HIF-1α is a transcriptional regulator of A2B.
Silencing of A2B in liver cancer cell suppressed cell growth and proliferation. As increased expression of adenosine A2B was observed in liver cancer cells, we tested whether the direct knock-down of A2B expression could affect cell growth and proliferation in liver cancer cells. We transfected HepG2 (the hepatoblastoma cell line) cells with A2B-siRNA and maintained them for up to 96 h. The A2B-siRNA effectively inhibited A2B expressions compared to scr-siRNA (Fig. 4A) . Treatment with A2B-siRNA for 24 to 96 h significantly (P<0.001) decreased cell proliferation, as revealed by the BrdU assay (Fig. 4B) . Similarly, the MTT assay also showed that cell growth was greatly decreased when cells were treated with A2B-siRNA ( Fig. 4C) . Additionally, the relative cell viabilities were significantly (P<0.001) lowered after transfection of cells with A2B-siRNA ( Fig. 4D ). As A2B deficient liver cancer cells show consistent decrease in cell growth and proliferation, we could conclude that A2B takes an important role in liver cancer cell proliferation.
HIF-1α levels are associated with A2B transcript and protein levels in human liver cancer specimens. Solid tumors, including liver cancer, usually experience hypoxic conditions due to the fast growth (22) . To confirm the relationship between adenosine A2B receptor expression and human liver cancer, we tested A2B induction from both tumor tissues and the adjacent normal tissues came from identical individuals diagnosed as a liver cancer. As expected, HIF-1α protein expression was high in the five human liver cancer specimens compared to its expression in normal tissues. A2B protein expression levels were also increased, suggesting that HIF-1α correlates with A2B in tumors, according to the fold changes of HIF-1α and A2B densitometry results ( Fig. 5A-C) . Collectively, HIF-1α, as a master transcription factor, can bind to the A2B promoter region and induce expression of A2B, thereby promoting tumor growth and survival. Moreover, we also confirmed the higher level of A2B gene expression in the HCC specimens by qRT-PCR. By contrast, we found no associations between the expression levels of mRNAs of A1, A2A, or A3 between normal and HCC specimens (Fig. 5D ).
Discussion
In this study, we defined the various expression patterns of adenosine receptor isoforms from three different liver cancer cell lines and human liver cancer specimens. We found that the A2B expression patterns were persistently higher than those of A1, A2A, and A3 receptor subtypes in liver cancer cell lines when maintained under low-oxygen conditions. Those patterns were also observed in human liver cancers. Under the hypothesis that hypoxia-mediated HIF-1α activation leads to liver cancer cell proliferation by activating adenosine A2B receptors, we followed transcription factor binding assays utilizing A2B promoter constructs and constructs with site-directed mutagenesis and have identified HIF-1α as the key regulator of A2B-induction during hypoxic conditions. We also investigated loss-and gain-of-function using HIF-1α siRNA and overexpressing vectors. We found that the expression levels of A2B were modulated HIF-1α-dependently. In addition to this, echinomycin treatment dose-dependently inhibited A2B expressions under hypoxia, which indicate transcriptional induction of A2B by HIF-1α. We also showed that active deprivation of A2B expression by siRNA suppresses cell growth and proliferation of the hepatoblastoma cell line, HepG2. Those results indicate the activation of hepatic A2B signals during low oxygen condition is related to liver cancer cell proliferation. Consistent with our in vitro results, human liver cancer specimens showed elevated levels of HIF-1α along with A2B in both transcript and protein levels. These data implicate HIF-1α in the regulation of adenosine-elicited cancer growth in liver.
We have previously studied the HIF-1α stabilization during hypoxic conditions in liver cell lines (23) and identified the protective role of HIF-1α stabilization mediated by hypoxia-induced inhibition of succinate dehydrogenase, concomitant increases in glycolytic capacity, and improved tricarboxylic acid (TCA) cycle function in alveolar epithelium (24) . Also the pharmacologic studies with HIF activator or inhibitor treatment implicated HIF-1α-stabilization increases in liver cancer proliferation (25) .
On the other hand, studies have shown the key roles of adenosine in HCC cell proliferation (26) . Adenosine also upregulates endothelial cell proliferation by associating with A2B in porcine and rat arterial endothelial cells (27) . In retinal endothelial cells, activated A2B can initiate neovascularization through increased angiogenic growth factor expression (28) . In contrast, adenosine inhibits the growth of cardiac fibroblasts and aortic and vascular smooth muscle cells through the activation of A2B, in addition to increasing the proliferation of peripheral micro-vessels, but exerts the opposite effect on cardiac tissue and capillaries (29) . Thus, A2B can promote cancer proliferation and expansion by initiating neovascularization around cancer masses (30) .
We showed that A2B is induced under hypoxic conditions. In general, solid cancers, such as breast, lung, colon, and prostate cancers undergo similar low-oxygen growth conditions (31); moreover, to maintain homeostasis under low-oxygen supply conditions, specific genes need to be systematically activated and expressed or inactivated.
It was previously reported that bleomycin, a chemical irritant which induce HIF-1α, can mediate A2B receptor expression while inducing adenosine accumulation in acute lung injury (32) . In addition, HIF-1α mediated expression of A2B in endothelial cells (15) , lung injury (18), breast cancer (19) , and dendritic cells (33) has been reported. Nevertheless, the hypoxia mediated A2B signaling mechanism promoting liver cancer cell proliferation is yet to be elucidated.
Other researchers have suggested that adenosine receptors are highly controlled and, thus, adenosine responses might be regulated by the surface expression of adenosine receptors. Consistent with our study, Eltzschig et al reported that microarray analyses of cDNA derived from endothelial cells subjected to various periods of hypoxia revealed significant changes in the adenosine receptor's profiles, wherein the prominent phenotypic change favored A2B expression with concomitant downregulation of A1 and A2 subtypes (34) . In another study, Feoktistov and Biaggioni suggested that hypoxia increases A2B expression levels releasing vascular endothelial growth factor through decreasing adenosine (35) .
Human endothelial and smooth muscle cells have also been shown to express A2B (36) . Moreover, hypoxia reduces matrix metalloproteinase-9 (MMP-9) production by human monocyte-derived dendritic cells and requires the activation of adenosine A2B via the cAMP/protein kinase (PKA) signaling pathway (37, 38) . Collectively, these data suggest that A2B increases HIF-1α dependently under hypoxic conditions and might promote liver cancer cell proliferation.
In summary, we investigated the expressions of A2B and HIF-1α in liver cancer cells to find an association suggesting that under hypoxic conditions, HIF-1α induces A2B expression to maintain tumor proliferation. Our results show that the upregulated A2B plays a critical role in liver cancer cell growth, suggesting A2B as a potential target for drug design; thus, an effective A2B inhibitor might be useful for treating liver cancers.
